Efficacy and Safety of VB421 in Subjects With Thyroid Eye Disease (TED)

Efficacy and Safety of VB421 in Subjects With Thyroid Eye Disease (TED)

Study Type :
Interventional  (Clinical Trial)

Estimated Enrollment :
36 participants


Intervention Model:
Sequential Assignment

Intervention Model Description:
Up to 3 cohorts are planned, with each cohort receiving one of 3 different treatment doses

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Masking Description:
Double-masked, placebo-controlled

Primary Purpose:

Official Title:
A Phase 1b, Randomized, Double-Masked, Placebo-Controlled, Multiple Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of VB421 in Subjects With Thyroid Eye Disease (TED)

Estimated Study Start Date :
January 2023

Estimated Primary Completion Date :
September 2023

Estimated Study Completion Date :
December 2023

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 14, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine